Physician profile
Alan Kaneshige
NPI 1710957535
$10,808.85
in general payments reported to CMS, 2019-2025
20 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,493 · 2020: $69.38 · 2021: $181 · 2022: $82.61 · 2023: $188 · 2024: $643 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,361.75 | 2019-2021 | |
| Abiomed | $367.54 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $196.58 | 2021-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $115.24 | 2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.26 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $108.46 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $87.25 | 2021-2024 | Watchman Access System |
| Amgen INC. | $84.11 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $75.81 | 2021-2023 | Opsumit |
| Merck Sharp & Dohme LLC | $64.44 | 2022-2024 | Verquvo |
| Lantheus Medical Imaging, INC. | $50.53 | 2019-2025 | Definity |
| Astrazeneca Pharmaceuticals LP | $38.16 | 2019 | |
| Abbott Laboratories | $36.43 | 2019-2023 | Mitraclip |
| Esperion Therapeutics, INC. | $22.00 | 2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $17.29 | 2023 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.95 | 2019 | |
| Surmodics, INC. | $15.86 | 2023 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Sublime Radial Access Guide Sheath |
| Kiniksa Pharmaceuticals, LTD. | $15.67 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $12.85 | 2019 | |
| Edwards Lifesciences Corporation | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kaneshige listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.